Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Anygen Co., Ltd. (196300:KRX), powered by AI.
Anygen Co., Ltd. is currently trading at ₩5,080. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Anygen Co., Ltd. on Alpha Lenz.
Anygen Co., Ltd.'s P/E ratio is -74.1.
“Anygen Co., Ltd. trades at a P/E of -74.1 (undervalued) with modest ROE of -4.1%.”
Ask for details →Anygen Co., Ltd. is a prominent biotechnology company specializing in the research and development of peptide-based therapeutics and raw materials. This company focuses on the creation of cutting-edge peptide technologies that serve various applications in pharmaceuticals, cosmetics, and healthcare industries. By harnessing advanced biochemical methods, Anygen Co., Ltd. contributes significantly to the development of innovative drugs and cosmetic products, improving health and wellness worldwide. Operating within the competitive biotechnology sector, Anygen Co., Ltd. plays a pivotal role in advancing medical treatments and cosmetic formulations. Its expansive research operations are aimed at increasing the efficacy and safety of peptide-based solutions, which offer promising alternatives to conventional synthetic pharmaceuticals. As a key player in the biotechnology market, the company's innovations drive progress across multiple industries, showcasing its importance in both therapeutic and cosmetic advancements. Through collaborative efforts with other scientific entities and constant innovation, Anygen Co., Ltd. maintains its influence in the growing field of biotechnology, contributing substantially to the global pursuit of enhanced human health and quality of life.
“Anygen Co., Ltd. trades at a P/E of -74.1 (undervalued) with modest ROE of -4.1%.”
Ask for details →Anygen Co., Ltd. (ticker: 196300) is a company listed on KRX in the Basic Materials sector (Chemicals). Market cap is $47.6B.
The current price is ₩5,080 with a P/E ratio of -74.14x and P/B of 1.85x.
ROE is -4.13% and operating margin is -147.53%. Annual revenue is $5.0B.